logo
ProjectEnded

NEBU-ONE : A revolutionary method for anatomic pathology slides staining

The status, timeline and source of this project. A free account opens every field.

Source: EU Funding & Tenders Portal

Anatomic pathology laboratories (APL) across Europe have a responsibility to urgently modernize and sustain increasing efficiency, leverage automation, and foster patient safety. Misidentification errors in laboratories have the capability to cause devastating events, both at medical and economic level. It is estimated that 30% of cytological cell samples are misinterpreted as negative for cancer.

Status
Closed
Sector
Hospital, Manufacturing (Industrial)
Location
France
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about NEBU-ONE : A revolutionary method for anatomic pathology slides staining

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “NEBU-ONE : A revolutionary method for anatomic pathology slides staining” is an infrastructure initiative in the Hospital sector, located in France. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Anatomic pathology laboratories (APL) across Europe have a responsibility to urgently modernize and sustain increasing efficiency, leverage automation, and foster patient safety. Misidentification errors in laboratories have the capability to cause devastating events, both at medical and economic level. It is estimated that 30% of cytological cell samples are misinterpreted as negative for cancer. That represents 1.65 millions of samples per year. One of the most important problems for APL is the increase of the number of biological screening samples to be processed due to the lengthening of the lifetime and increased number of cancers. Only screening of cervical cancer, which represents today about 200 million tests worldwide and the market of about 1 milliard of euros, should double by 2020. Optana Technologies is developing a breakthrough medical device called NEBU-ONE, for highly improved and automated biological sample staining. NEBU-ONE contains a proprietary “nebulization heads” which deposits staining reagents in the form of aerosol (microdroplets) allowing them to penetrate much deeper and much faster into the tested samples (cells and tissues) compared to standard techniques. Often present cross-contamination between samples will be also decreased, as well as a consumption of expensive and pollutants reagents. All these will lead to increased quality of sample staining, improved accuracy of the analysis and interpretation and better diagnosis and patient care. It will allow Optana Technologies to become the reference method in the APLs and to grow rapidly in the European market. We plan to achieve the turnover of 4.3 M€ in 2020 and create 5 new highly qualified post. This feasibility study is essential to validate our innovative business model and NEBU-ONE before its transfer in routine laboratory practice and industrial production.

Location

Country

France

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Hospital, Manufacturing (Industrial)

Article published date

2026-01-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project